- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-6-6-24-24-mer
- Ligands
- 18 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
NAG-NAG.4: 5 residues within 4Å:- Chain F: N.134, T.136, S.141, W.142
- Ligands: BMA.5
No protein-ligand interaction detected (PLIP)NAG-NAG.13: 5 residues within 4Å:- Chain P: N.134, T.136, S.141, W.142
- Ligands: BMA.14
No protein-ligand interaction detected (PLIP)NAG-NAG.22: 5 residues within 4Å:- Chain Z: N.134, T.136, S.141, W.142
- Ligands: BMA.23
No protein-ligand interaction detected (PLIP)NAG-NAG.31: 5 residues within 4Å:- Chain 9: N.134, T.136, S.141, W.142
- Ligands: BMA.32
No protein-ligand interaction detected (PLIP)NAG-NAG.40: 5 residues within 4Å:- Ligands: BMA.41
- Chain j: N.134, T.136, S.141, W.142
No protein-ligand interaction detected (PLIP)NAG-NAG.49: 5 residues within 4Å:- Ligands: BMA.50
- Chain t: N.134, T.136, S.141, W.142
No protein-ligand interaction detected (PLIP)- 6 x BMA: beta-D-mannopyranose(Non-functional Binders)
BMA.5: 1 residues within 4Å:- Ligands: NAG-NAG.4
No protein-ligand interaction detected (PLIP)BMA.14: 1 residues within 4Å:- Ligands: NAG-NAG.13
No protein-ligand interaction detected (PLIP)BMA.23: 1 residues within 4Å:- Ligands: NAG-NAG.22
No protein-ligand interaction detected (PLIP)BMA.32: 1 residues within 4Å:- Ligands: NAG-NAG.31
No protein-ligand interaction detected (PLIP)BMA.41: 1 residues within 4Å:- Ligands: NAG-NAG.40
No protein-ligand interaction detected (PLIP)BMA.50: 1 residues within 4Å:- Ligands: NAG-NAG.49
No protein-ligand interaction detected (PLIP)- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
NAG.6: 2 residues within 4Å:- Chain G: I.281, N.315
Ligand excluded by PLIPNAG.7: 2 residues within 4Å:- Chain H: I.281, N.315
Ligand excluded by PLIPNAG.8: 3 residues within 4Å:- Chain I: K.276, I.281, N.315
Ligand excluded by PLIPNAG.9: 2 residues within 4Å:- Chain J: I.281, N.315
Ligand excluded by PLIPNAG.15: 2 residues within 4Å:- Chain Q: I.281, N.315
Ligand excluded by PLIPNAG.16: 2 residues within 4Å:- Chain R: I.281, N.315
Ligand excluded by PLIPNAG.17: 3 residues within 4Å:- Chain S: K.276, I.281, N.315
Ligand excluded by PLIPNAG.18: 2 residues within 4Å:- Chain T: I.281, N.315
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain 0: I.281, N.315
Ligand excluded by PLIPNAG.25: 2 residues within 4Å:- Chain 1: I.281, N.315
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain 2: K.276, I.281, N.315
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain 3: I.281, N.315
Ligand excluded by PLIPNAG.33: 2 residues within 4Å:- Chain a: I.281, N.315
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain b: I.281, N.315
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain c: K.276, I.281, N.315
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain d: I.281, N.315
Ligand excluded by PLIPNAG.42: 2 residues within 4Å:- Chain k: I.281, N.315
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain l: I.281, N.315
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain m: K.276, I.281, N.315
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain n: I.281, N.315
Ligand excluded by PLIPNAG.51: 2 residues within 4Å:- Chain u: I.281, N.315
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain v: I.281, N.315
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain w: K.276, I.281, N.315
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain x: I.281, N.315
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bandyopadhyay, A. et al., Cryo-EM structure of SINV/EEEV in complex with a potently neutralizing human antibody IgG EEEV-373. To Be Published
- Release Date
- 2025-06-11
- Peptides
- IgG EEEV-373 Heavy chain: AKU4eo
IgG EEEV-373 Light chain: BLV5fp
Spike glycoprotein E1: CDEFMNOPWXYZ6789ghijqrst
E2 glycoprotein: GHIJQRST0123abcdklmnuvwx - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1K
1U
14
1e
1o
1B
2L
2V
25
2f
2p
2C
AD
BE
CF
DM
AN
BO
CP
DW
AX
BY
CZ
D6
A7
B8
C9
Dg
Ah
Bi
Cj
Dq
Ar
Bs
Ct
DG
aH
bI
cJ
dQ
aR
bS
cT
d0
a1
b2
c3
da
ab
bc
cd
dk
al
bm
cn
du
av
bw
cx
d
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-6-6-24-24-mer
- Ligands
- 18 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 6 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
- 6 x BMA: beta-D-mannopyranose(Non-functional Binders)
- 24 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Bandyopadhyay, A. et al., Cryo-EM structure of SINV/EEEV in complex with a potently neutralizing human antibody IgG EEEV-373. To Be Published
- Release Date
- 2025-06-11
- Peptides
- IgG EEEV-373 Heavy chain: AKU4eo
IgG EEEV-373 Light chain: BLV5fp
Spike glycoprotein E1: CDEFMNOPWXYZ6789ghijqrst
E2 glycoprotein: GHIJQRST0123abcdklmnuvwx - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
1K
1U
14
1e
1o
1B
2L
2V
25
2f
2p
2C
AD
BE
CF
DM
AN
BO
CP
DW
AX
BY
CZ
D6
A7
B8
C9
Dg
Ah
Bi
Cj
Dq
Ar
Bs
Ct
DG
aH
bI
cJ
dQ
aR
bS
cT
d0
a1
b2
c3
da
ab
bc
cd
dk
al
bm
cn
du
av
bw
cx
d